EUCTR2006-001168-22-GB进行中（未招募）1 期
A phase II, randomized, open, partially controlled study to evaluate the safety and immunogenicity of different formulations of a pandemic influenza vaccine candidate (split virus formulation adjuvanted with AS03) given following a two-administration schedule (21 days apart) in children between 3 and 9 years of age. - H5N1-009, H5N1-022 STG 009 cohort 2, H5N1-023 STG 009 cohort 3
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 405
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Children who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.
- •Children aged between and including 3 and 9 years of age at the time of first vaccination.
- •Written informed consent obtained from the parent or guardian of the subject.
- •Healthy children as established by medical history and history-directed clinical examination before entering the study.
- •Subjects who are likely to reside in the vicinity of the study center for the duration of the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the H5N1 vaccine candidate within 30 days prior to the enrolment in this study, or planned use during the study period.
- •Administration of licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of a vaccine not foreseen by the study protocol up to 30 days after the second vaccination, with the exception of routine childhood inoculations which cannot be delayed, but which must not be administered on the same day as the H5N1 vaccine candidate.
- •Administration of the interpandemic influenza vaccine (NH 2006/2007 or SH 2007) prior to Day 0 or planned during the study. However, study participants eligible to receive the annual interpandemic influenza vaccine (in accordance with DOH recommendations), may receive the annual vaccination at least 21 days prior to Day 0 or after Day 51 and up to Day 159.
- •Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the enrolment in this study. (For corticosteroids, this will mean prednisone, or equivalent, <= 0.5 mg/kg/day. Inhaled and topical steroids are allowed).
- •Any chronic drug therapy to be continued during the study period, with the exception of inhalative treatment for seasonal allergies or asthma.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
- •Acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination.
- •History of hypersensitivity to vaccines.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccines such as egg protein or thiomersal.
- •History of any neurological disorders or seizures.
- •Acute disease at the time of enrolment. (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhoea, mild upper respiratory infection with or without low-grade febrile illness, i.e. axillary temperature <37.5°C).
- •Administration of immunoglubulins and/or any blood products within the three months prior to the enrolment in this study or planned during the study.
- •Any condition which, in the opinion of the investigator, renders the subject unfit for participation in the study.
研究者
相似试验
进行中（未招募）
1 期
Immunogenicity and safety of two formulations of GSK Biologicals? pneumococcal vaccine (2830929A and 2830930A) when administered in healthy infants.EUCTR2011-005743-27-ESGlaxoSmithKline Biologicals953
进行中（未招募）
1 期
Immunogenicity and safety of two formulations of GSK Biologicals’ pneumococcal vaccine (2830929A and 2830930A) when administered in healthy infants.EUCTR2011-005743-27-CZGlaxoSmithKline Biologicals940
进行中（未招募）
不适用
Immunogenicity and safety of two formulations of GSK Biologicals’ pneumococcal vaccine (2830929A and 2830930A) when administered in healthy infants.3-dose primary vaccination against Streptococcus pneumoniae and Haemophilus influenzae in healthy infants between 6-12 weeks of age at the time of the first vaccination and booster vaccination at 12-15 months of age.MedDRA version: 16.0Level: LLTClassification code 10042196Term: Streptococcus pneumoniae secondary bacterial infection of acute bronchitisSystem Organ Class: 100000004862MedDRA version: 16.0Level: LLTClassification code 10042197Term: Streptococcus pneumoniae septicaemiaSystem Organ Class: 100000004862MedDRA version: 16.0Level: LLTClassification code 10042195Term: Streptococcus pneumoniae pneumoniaSystem Organ Class: 100000004862MedDRA version: 16.0Level: LLTClassification code 10042194Term: Streptococcus pneumoniae meningitisSystem Organ Class: 100000004862MedDRA version: 16.0Level: LLTClassification code 10018954Term: Haemophilus influenzae secondary bacterial infection of acute bronchitisSystem Organ Class: 100000004862MedDRA version: 16.0Level: LLTClassification code 10054642Term: Streptococcus pneumoniae septicemiaSystem Organ Class: 100000004862MedDRA version: 16.0Level: LLTClassification code 10018953Term: Haemophilus influenzae meningitisSystem Organ Class: 100000004862MedDRA version: 16.0Level: LLTClassification code 10018952Term: Haemophilus influenzae infectionSystem Organ Class: 100000004862MedDRA version: 16.0Level: LLTClassification code 10058214Term: Septicaemia due to haemophilus influenzae (H. influenzae)System Organ Class: 100000004862MedDRA version: 16.0Level: LLTClassification code 10035680Term: Pneumonia due to Haemophilus influenzae (H. influenzae)System Organ Class: 100000004862EUCTR2011-005743-27-PLGlaxoSmithKline Biologicals940
进行中（未招募）
不适用
Immunogenicity and safety of two formulations of GSK Biologicals’ pneumococcal vaccine (2830929A and 2830930A) when administered in healthy infants.3-dose primary vaccination against Streptococcus pneumoniae and Haemophilus influenzae in healthy infants between 6-12 weeks of age at the time of the first vaccination and booster vaccination at 12-15 months of age.MedDRA version: 14.1Level: LLTClassification code 10042196Term: Streptococcus pneumoniae secondary bacterial infection of acute bronchitisSystem Organ Class: 100000004862MedDRA version: 14.1Level: LLTClassification code 10042197Term: Streptococcus pneumoniae septicaemiaSystem Organ Class: 100000004862MedDRA version: 14.1Level: LLTClassification code 10042195Term: Streptococcus pneumoniae pneumoniaSystem Organ Class: 100000004862MedDRA version: 14.1Level: LLTClassification code 10042194Term: Streptococcus pneumoniae meningitisSystem Organ Class: 100000004862MedDRA version: 14.1Level: LLTClassification code 10018954Term: Haemophilus influenzae secondary bacterial infection of acute bronchitisSystem Organ Class: 100000004862MedDRA version: 14.1Level: LLTClassification code 10054642Term: Streptococcus pneumoniae septicemiaSystem Organ Class: 100000004862MedDRA version: 14.1Level: LLTClassification code 10018953Term: Haemophilus influenzae meningitisSystem Organ Class: 100000004862MedDRA version: 14.1Level: LLTClassification code 10018952Term: Haemophilus influenzae infectionSystem Organ Class: 100000004862MedDRA version: 14.1Level: LLTClassification code 10058214Term: Septicaemia due to haemophilus influenzae (H. influenzae)System Organ Class: 100000004862MedDRA version: 14.1Level: LLTClassification code 10035680Term: Pneumonia due to Haemophilus influenzae (H. influenzae)System Organ Class: 100000004862EUCTR2011-005743-27-DEGlaxoSmithKline Biologicals940
进行中（未招募）
不适用
A study of HM10560A, a long-acting growth hormone product, for treatment of adult patients suffering from growth hormone deficiencyEUCTR2011-001826-61-HUHanmi Pharmaceutical Co., Ltd.65